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Background: The management of cervical lymph node metastases from an unknown primary tumor remains a
controversial subject. Recently, Positron Emission Tomography (PET) has proved useful in the detection of these
tumors, even after an unsuccessful conventional diagnostic workup. This study was performed to assess the role of
PET in the detection of occult primary head and neck carcinomas.
Methods: A retrospective analysis of a four year period at a tertiary referral oncology hospital was conducted.
Results: Of the 49 patients with cervical metastases of carcinoma from an unknown primary, PET detected a
primary in 9 patients and gave 5 false positive and 4 false negative results. Detection rate, sensitivity, specificity and
accuracy were of 18.4%, 69.2%, 86.1% and 81.6%, respectively. PET was also of substantial benefit in detecting
distant metastatic disease and, thus, altered therapeutic strategies in a significant amount of patients.
Conclusions: Therefore, PET is a valuable tool in the management of patients with occult primary head and neck
carcinoma, not only because it provides additional information as to the location of primary tumors, but also due to
the fact that it can detect unexpected distant metastases.
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Positron emission tomography (PET) is a functional
image modality that characterizes the different tissues of
the body according to perfusion and metabolic activity.
18 F-fluoro-2-deoxy-D-glucose (FDG), a radioactively la-
beled glucose analogue, is utilized due to its capacity to
emit positrons that can be accurately localized by PET
imaging. As tumor cells have an increased uptake of glu-
cose, FDG accumulates within these cells, producing a
“hot spot” on the PET image that can, therefore, be dis-
tinguished from surrounding normal tissue [1,2].
The utility of PET imaging has been demonstrated in
the diagnosis and initial staging of head and neck tumors
as well as in the evaluation of persistent or recurrent dis-
ease following radiotherapy [3,4]. Others have shown the
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[5,6]. One advantage of PET over other imaging modal-
ities, such as computed tomography (CT) or magnetic
resonance imaging (MRI), is that, since PET imaging
visualizes metabolic processes in vivo, relatively small
tumors can be detected before structural changes have
taken place, as long as they are metabolically active [7].
In fact, previously unapparent tumors, as small as 3 mm,
have been detected by PET imaging [8]. PET can also dif-
ferentiate normal from metastatic lymph nodes, sinus
malignancy from secretions and tumor from fibrosis [7].
Furthermore, it is a non invasive technique that supplies
full body information with only one session [9].
However, there are physiological areas of increased up-
take in a normal PET scan which are prone to misinter-
pretation and can lead to false positive results. In the
head and neck, these sites include the thyroid and saliv-
ary glands, muscles, Waldeyer’s ring and the brain [7].
False positive results can also be caused by inflammationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lution of PET scan which produces an anatomically in-
accurate image. Significant improvement has been made
at this level with PET/CT fusion technology, where PET
imaging is supplemented by an overlay of a CT scan
image, with improved sensibility and specificity [2,10].
Metastatic carcinoma in cervical lymph nodes of un-
known primary origin is rare and accounts for only 3 to
5% of all head and neck tumors [2]. The most frequent
histological finding is squamous cell carcinoma. Certain
theories propose that there may not actually be a pri-
mary tumor in the aerodigestive tract and rather that the
carcinoma has developed within a branchial cleft cyst or
may have suffered spontaneous regression [11]. Although
intriguing, little or no evidence exists to support these
theories and it is more likely that there is, in fact, a sub-
clinical primary tumor that cannot be detected by con-
temporary methods [2].
Traditional diagnostic evaluation for an unknown primary
tumor consists of a thorough clinical examination including
fiberoptic endoscopy of all the mucosa of the superior aero-
digestive tract, CT and/or MRI followed by panendoscopy
with directed biopsies and tonsillectomy [12]. Contrast-
enhanced CT scans should cover the area from the skull
base to the level of the thoracic inlet and either chest radi-
ography or thoracic CT should be performed [2]. More
recently, attention has been focused on PET using FDG in
the diagnostic workup of these patients, although contro-
versy still exists as to the real benefit [1,5,8,9,11,12]. This
study was performed to clarify the potential role of PET in
the detection of occult primary head and neck carcinoma.
Methods
A retrospective study of all the patients diagnosed with
an occult primary carcinoma of the head and neck re-
gion was conducted at the Francisco Gentil Portuguese
Institute of Oncology of Porto (IPOPFG), a tertiary refer-
ral oncology hospital, within a 4 year period (between
2006 and 2009). All patients had histopathological proof
of carcinoma of the cervical lymph nodes and had also
undergone a comprehensive head and neck physical
examination including fiberoptic endoscopy. Only
patients, that had previously undergone CT evaluation of
the head and neck and either chest radiography or thor-
acic CT to rule out a primary tumor, were eligible for
this study. After the initial diagnostic evaluation had
been negative for primary tumor, these patients had then
undergone total-body PET imaging using FDG at the
IPOPFG. Patients without confirmation of PET-positive
findings (through tissue biopsies) were not included.
Results
A total of 49 consecutive cases of occult primary head
and neck carcinoma at the IPOPFG, between 2006 and2009, met the above inclusion criteria. The medical
records of these 49 patients were reviewed (Table 1).
Forty-four (89.8%) were men and 5 (10.2%) were women.
Overall, the mean age of the study group was 57.3 years,
with a range between 36 and 81 years. The results of the
neck staging included N1 in 8 patients, N2a in 10
patients, N2b in 10 patients, N2c in 1 patient and N3 in
20 patients. The histological diagnosis was of squamous
cell carcinoma in 30 patients, poorly differentiated car-
cinoma in 12 patients, undifferentiated carcinoma in 3
patients and adenocarcinoma in 4 patients. With respect
to topographical distribution, the upper and middle cer-
vical lymph nodes were most frequently involved. Neck
level II was involved in 75.5% of patients, whilst levels III
and V were involved in 42.9% and 30.6% of cases, re-
spectively. Levels IV and I were seldom found to harbor
metastatic lymph nodes (16.3% and 10.2%, respectively)
and no patient presented with involvement of level VI.
The PET scan was positive for cervical lymph node
metastases in all 49 patients. In 14 patients, a possible
primary tumor site was indicated by PET. Of these 14
patients, 9 were confirmed histopathologically through
tissue biopsies as being squamous cell carcinomas. In the
other 5 cases, directed biopsies were negative for tumor
(false positive PET findings). Of the 9 primary tumors
detected by PET, 4 were situated in the oropharynx (2
base of tongue, 1 palatine tonsil and 1 other oropharyn-
geal site), 1 in the hypopharynx, 1 in the sinonasal re-
gion, 1 in the parotid gland, 1 in the lung and 1 in the
esophagus. Our overall detection rate was 18.4%. Of the
5 false positive results, 2 were located in the nasophar-
ynx, 1 in the palatine tonsil, 1 in the hypopharynx and 1
in the supraglottis (Figure 1). Our overall false positive
rate was 35.7%. On the other hand, PET detected pos-
sible distant metastases that had not been previously
documented in 18 patients, which corresponds to a total
of 36.7%. These sites included bone metastases in 10
patients, extracervical lymph nodes in 9, hepatic metas-
tasis in 5 and pulmonary metastases in 4. Interestingly, 3
out of the 4 patients with adenocarcinoma had infraclavi-
cular disease and patients with only lower neck involve-
ment (areas IV or V) were also associated with a higher
percentage of disease below the clavicles (47.4%).
In addition, 4 patients had false-negative PET findings
with positive tissue biopsies. The mean follow-up time
period surpassed between PET and primary tumor diag-
nosis was 10 months (with a range between 3 and
17 months). These were found to be squamous cell car-
cinomas of the palatine tonsil (2 cases) and piriform
sinus (2 cases).
On a whole, the mean follow-up for all patients was
22.3 months. PET altered the treatment protocols in a total
of 42.9% of patients. These changes, in 21 patients, were at-
tributable to either the identification of a primary tumor,
Table 1 Patient demographics.
Patient
no.
Sex Age
(yrs)
Tumor
stage
Diagnosis
(tumor type)
Localization
of cervical
lymph node
metastases
PET result Result of
directed
biopsy
Did PET
result alter
treatment
strategy?
1 M 55 N3 PDC II, III negative n/a No
2 M 57 N1 SCC III negative n/a No
3 M 65 N1 SCC II negative n/a No
4 M 65 N2a SCC II negative n/a No
5 F 72 N2a UC II negative n/a No
6 M 72 N3 SCC V pulmonary metastases n/a Yes
7 M 50 N1 SCC II hypopharynx SCC Yes
8 M 55 N3 SCC II, III, V negative n/a No
9 M 40 N1 SCC II oropharynx; bone and
hepatic metastases
SCC Yes
10 M 69 N2b UC II,III bone and hepatic
metastases
n/a Yes
11 M 44 N3 SCC II, III negative n/a No
12 M 48 N2b SCC II negative n/a No
13 M 70 N2a SCC II, III negative n/a No
14 F 57 N1 PDC I base of tongue SCC Yes
15 M 48 N2a PDC II nasopharynx; bone and
extracervical lymph node
metastases
negative Yes
16 M 48 N3 Adenocarcinoma II, III negative n/a No
17 M 54 N3 SCC II, III negative n/a No
18 M 47 N2c SCC III, IV hypopharynx negative No
19 M 57 N2b PDC II, III, V hepatic metastases n/a Yes
20 M 68 N2a SCC III supraglottis negative No
21 M 36 N3 Adenocarcinoma II, III, IV, V extracervical lymph node
metastases
n/a Yes
22 M 68 N3 SCC II, V negative n/a No
23 M 44 N3 SCC II, III, IV, V palatine tonsil negative No
24 M 45 N2a PDC II extracervical lymph node
metastases
n/a Yes
25 F 56 N2b Adenocarcinoma V bone and pulmonary
metastases
n/a Yes
26 M 53 N3 PDC II, III bone metastases n/a Yes
27 M 68 N3 SCC II, III lung (primary) SCC Yes
28 M 47 N2a SCC II negative n/a No
29 M 46 N3 SCC II, V negative n/a No
30 M 75 N2b PDC I, II, V parotid gland SCC Yes
31 M 55 N3 SCC II, III negative n/a No
32 M 56 N2b PDC II negative n/a No
33 M 61 N2a SCC IV negative n/a No
34 F 51 N3 SCC II palatine tonsil SCC Yes
35 M 48 N1 PDC I bone metastases n/a Yes
36 M 61 N3 SCC II, III negative n/a No
37 M 58 N2b SCC II, III nasopharynx negative No
38 F 81 N1 SCC IV negative n/a No
39 M 78 N1 SCC V sinonasal primary and
extracervical lymph node
metastases
SCC Yes
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40 M 69 N2a PDC II hepatic metastases n/a Yes
41 M 60 N3 SCC II, III, IV bone and extracervical lymph
node metastases
n/a No
42 M 52 N3 PDC II, V pulmonary and hepatic
metastases
n/a Yes
43 M 73 N3 SCC II, V negative n/a No
44 M 56 N3 PDC II, III bone and extracervical
lymph node metastases
n/a No
45 M 69 N3 SCC IV, V esophageal primary, bone and
extracervical lymph node
metastases
SCC Yes
46 M 45 N2a Adenocarcinoma V extracervical lymph node
metastases
n/a Yes
47 M 60 N2b SCC I, II pulmonary, bone and
extracervical lymph
node metastases
n/a No
48 M 54 N2b SCC I, II base of tongue SCC Yes
49 M 44 N2b UC II, III, IV, V negative n/a No
PDC: poorly differentiated carcinoma; SCC: squamous cell carcinoma; UC: undifferentiated carcinoma; n/a: not applicable.
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Total PET results determined a sensitivity of 69.2%, a speci-
ficity of 86.1% and an accuracy of 81.6%.
Discussion
Despite advanced radiological imaging methods, be-
tween 3 and 5% of all head and neck tumors will be
diagnosed as being of unknown primary origin [2].
The vast majority are squamous cell carcinomas.
Some authors have demonstrated that most of these
tumors, when identified, are located in the palatine
tonsil or the base of tongue area [13] and most ad-
vocate systematic bilateral tonsillectomy [14-16].
However, the real benefit of new imaging modalities
and the validity of management strategies remain
contreversial [2,11].
In order to reduce the heterogeneity of our study, we
selected only those patients that had proven carcinomaFigure 1 Case example of a false positive FDG-PET finding. Axial, sagittal an
uptake in the supraglottic region. The area was free of tumor when examin
were negative for neoplasia.in a cervical lymph node, excluding patients, for ex-
ample, with melanomas and tumors of hematopoietic
origin. With the intention of evaluating the additional
benefit provided by PET over conventional radiologic
imaging and workup, all patients included in this study
had previously undergone complete clinical and endo-
scopic office examination, head and neck CT and, at
least, chest radiography.
After conventional workup, our primary tumor detec-
tion rate with PET was found to be 18.4%. This corre-
sponds to 9 patients with a histopathologically confirmed
positive PET result out of a total 49 patients with un-
known primary head and neck carcinoma. Detection
rates vary in the literature from 5 to 73%, including a
mean detection rate of 24.5% suggested by a large review
[1]. Besides the ability to detect occult primary tumors,
PET can also serve as a screening tool for distant syn-
chronous primaries or metastatic disease [12]. Our PETd coronal views of the PET scan are displayed and demonstrate an
ed through careful panendoscopy and multiple deep directed biopsies
Suspicious neck mass
Full head and neck 
examination
Fiberoptic endoscopy
Primary found Primary not found
Work-up & treat accordingly FNA or open
biopsy
Carcinoma Melanoma, hematopoietic or 
thyroid tumors
Work-up & treat accordingly
Head and neck CT
Chest X-ray or CT
Primary found Primary not found
Work-up & treat accordingly PET-CT scan
Possible primary Primary not found
Endoscopic examination 
under general anesthesia 
with directed biopsies
Endoscopic examination 
under general anesthesia 
with multiple biopsies
Primary found Primary not found
Treat accordingly Treatment protocols for occult 
primary tumors
Figure 2 Management flow chart for unknown primary head and neck carcinoma.
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the lung and another in the esophagus. Although these
could possibly be labeled as synchronous primaries with
the true head and neck carcinoma remaining unknown,
they were undetected by other imaging techniques and
treatment strategies were significantly altered in these
patients. Furthermore, possible distant metastases were
identified in 18 patients (36.7%). This result is quite
higher than that found in the literature [1,17], although
this is probably due to the large number of advanced
tumor stage (N3) cases in our series. The importance of
whole body PET in the detection of distant disease
should be stressed, especially when the lower neck is
involved. In our study almost half (47.4%) of these
patients had unexpected infraclavicular primaries or me-
tastases and three of four patients with adenocarcinoma
(75%) had pathology below the clavicles.
PET sensitivity in the current review (69.2%) was slightly
lower than in most studies [1]. The 4 false negative results
that were found emphasize the fact that a negative PET scan
does not necessarily rule out the presence of a primary
tumor and discard the need for further investigation [12].
Possible causes for such a low sensitivity in our review may
be a low tumor uptake of FDG due to tumor differentiation
or small size or a high background signal of Waldeyer’s ring
[1]. This could, perhaps, justify the failure to detect the two
cases of palatine tonsil carcinoma. However, there is always
the possibility that there is no primary tumor to begin with,
which would significantly reduce the number of true posi-
tives [9].
One major weakness of PET in the detection of occult
primary tumors is the high false positive rate and low
specificity [1]. Due to the high percentage of false posi-
tives, some authors have found that there is a lack of
benefit in using PET, but suggest that meticulous biopsy
sampling and new tracers may ameliorate this aspect
[11]. We obtained, in our series, a false positive rate of
35.7% and a specificity of 86.1%. This is consistent with
or even somewhat better than previous reviews [1].
Nevertheless, the percentage of false positives is still
fairly high. Proposed reasons include high physiologic
uptake by the tonsils and muscles of mastication, inflam-
mation and benign tumors [11,17]. Overall, PET helped
identify 9 primary tumors which had previously gone un-
detected. It guided the surgeon to a potential primary
tumor site for deep tissue biopsies. 31 patients were con-
sidered as having true negative PET scans, as no primary
tumor was detected during a mean follow-up period of
22.3 months. This gives a total accuracy of 81.6%. A pro-
posed management flow chart is shown in figure 2.
Among other factors that must be considered when
opting for PET imaging in the management of
patients with unknown primary head and neck car-
cinoma are economic issues and availability. Mostreports indicate that perhaps PET scanning is not
cost effective [2]. Nonetheless, costs are comparable
to whole body MRI [1]. On the other hand, no more
than a few PET scans exist nationwide in Portugal,
limiting availability to major referral centers.
Conclusions
PET imaging is thus a valuable tool in the detection of
occult primary head and neck carcinomas. Not only does
it provide additional information as to the location of
primary tumors, but it can also help detect unexpected
distant metastases. As a result, therapeutic strategies and
long-term prognosis are influenced by PET in a substan-
tial number of these patients.
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